Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
Fernando Bril, Michael J. McPhaul, Michael P. Caulfield, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 290-297
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1128
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 366
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 246
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 235
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
Stephen Harrison, Vlad Ratziu, Jérôme Boursier, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 11, pp. 970-985
Open Access | Times Cited: 192
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Isabel Graupera, Maja Thiele, Miquel Serra‐Burriel, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 11, pp. 2567-2576.e6
Open Access | Times Cited: 163
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
Stefano Ciardullo, Tommaso Monti, Gianluca Perseghin
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 519-525
Open Access | Times Cited: 144
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 144
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 115
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 112
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
Arun J. Sanyal, Julie Foucquier, Zobair M. Younossi, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 247-259
Open Access | Times Cited: 107
Defining comprehensive models of care for NAFLD
Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 10, pp. 717-729
Closed Access | Times Cited: 103
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 5, pp. 575-594
Open Access | Times Cited: 73
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, et al.
Diabetes Care (2023) Vol. 46, Iss. 7, pp. 1354-1362
Open Access | Times Cited: 71
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 70
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, S. Kahl, Kalliopi Pafili, et al.
Metabolism (2020) Vol. 111, pp. 154299-154299
Open Access | Times Cited: 131
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros
Metabolism (2020) Vol. 111, pp. 154320-154320
Open Access | Times Cited: 121
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores
Antonio De Vincentis, Federica Tavaglione, Oveis Jamialahmadi, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 3, pp. 658-673
Open Access | Times Cited: 92
Preparing for the NASH Epidemic: A Call to Action
Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, et al.
Gastroenterology (2021) Vol. 161, Iss. 3, pp. 1030-1042.e8
Open Access | Times Cited: 78
Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics
Laurent Castéra
Liver International (2020) Vol. 40, Iss. S1, pp. 77-81
Closed Access | Times Cited: 73
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
Chi‐Ho Lee, David Tak Wai Lui, Karen SL Lam
Journal of Diabetes Investigation (2022) Vol. 13, Iss. 6, pp. 930-940
Open Access | Times Cited: 63
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Grazia Pennisi, Marco Enea, Vincenzo Falco, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 195-211
Open Access | Times Cited: 32
Circulating miRNAs associated with nonalcoholic fatty liver disease
Amila Iriskic Atic, Maja Thiele, Alexander Munk, et al.
AJP Cell Physiology (2023) Vol. 324, Iss. 2, pp. C588-C602
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top